Acumen Pharmaceuticals (ABOS) Return on Capital Employed (2021 - 2026)
Acumen Pharmaceuticals (ABOS) reported Return on Capital Employed of 115.77% for Q1 2026, down 5322.0% on a YoY basis from 2.22% in Q1 2025, and up 4.16% sequentially from 120.79% in Q4 2025.
Acumen Pharmaceuticals (ABOS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 6 years of Return on Capital Employed data on file, last reported at 115.77% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 5322.0% year-over-year to 115.77%; the trailing twelve-month figure through Mar 2026 stood at 115.77% (down 5322.0% YoY), and the FY2025 full-year result was 82.06%, down 3589.0% from the prior year.
- Return on Capital Employed climbed to 115.77% in Q1 2026, from 120.79% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.3% in Q1 2022 to a low of 120.79% in Q4 2025.
- A 5-year average of 46.99% and a median of 27.43% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 466 bps in 2024 and plunged 7020 bps in 2025, its largest moves.
- Tracing ABOS's Return on Capital Employed over 5 years: stood at 23.55% in 2022, then gained by 9 bps to 21.43% in 2023, then sank by 136 bps to 50.59% in 2024, then slumped by 139 bps to 120.79% in 2025, then rose by 4 bps to 115.77% in 2026.
- Business Quant data shows ABOS's Return on Capital Employed at 115.77% in Q1 2026, 120.79% in Q4 2025, and 102.31% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Acumen Pharmaceuticals | 140.98 Mn | 140.98 Mn | - | -115.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115.77% |
| Dec 31, 2025 | -120.79% |
| Sep 30, 2025 | -102.31% |
| Jun 30, 2025 | -88.16% |
| Mar 31, 2025 | -62.55% |
| Dec 31, 2024 | -50.59% |
| Sep 30, 2024 | -36.01% |
| Jun 30, 2024 | -27.43% |
| Mar 31, 2024 | -22.14% |
| Dec 31, 2023 | -21.43% |
| Sep 30, 2023 | -25.20% |
| Jun 30, 2023 | -30.00% |
| Mar 31, 2023 | -26.80% |
| Dec 31, 2022 | -23.55% |
| Sep 30, 2022 | -19.62% |
| Jun 30, 2022 | -15.17% |
| Mar 31, 2022 | -11.30% |
| Dec 31, 2021 | -8.61% |